Median Technologies Presents eyonis LCS at Conferences
The presentations at ISPOR 2025 and ATS 2025 will highlight the clinical and economic benefits of eyonis LCS, showcasing its ability to optimize lung cancer screening and diagnosis. As Median Technologies moves forward with its FDA 510K application, the company is well-positioned to bring its innovative technology to the U.S. market and make a lasting impact on the medical imaging industry.
Median Technologies will showcase its eyonis LCS Software as a Medical Device (SaMD) for lung cancer screening at two major health conferences in North America, highlighting its potential to optimize detection and diagnosis of lung cancer.
The company will present scientific posters at the ISPOR 2025 and ATS 2025 International Conference, demonstrating the projected U.S. economic benefit and positive data from the pivotal trial REALITY. The eyonis LCS software uses AI to detect and diagnose lung cancer in Low Dose Computed Tomography (LDCT) images, aiming to enhance early detection and characterization, reduce unnecessary procedures, and lead to earlier diagnoses.
The FDA 510K application for eyonis LCS U.S. marketing authorization is scheduled for submission shortly, with clearance and commercialization expected late this year. This regulatory approval is a significant step forward for Median Technologies in the U.S. market, allowing the company to expand the use of its medical imaging software and strengthen its presence in the country.
With its commitment to innovation and expansion, Median Technologies is poised to make a significant impact in the medical imaging industry, particularly in the field of lung cancer screening. The company's eyonis LCS software has the potential to improve patient outcomes and reduce healthcare costs, making it a valuable tool for medical professionals and patients alike.